Sources on June 15, 2026, said a major new study finds that women taking Ozempic Wegovy Mounjaro and Zepbound are about 30% less likely.
The development also coincided with Researchers and health authorities published findings adding to the scientific and medical evidence base.
Official statements supplied more information. Pricing and insurance coverage remain central questions as the drug advances toward broader clinical use. Clinical trials of a new oral GLP-1 medication showed dramatic improvements in blood sugar control and significant weight loss in type 2 diabetes patients. Authorities also noted that A large study found women taking Ozempic, Wegovy, Mounjaro, or Zepbound were about 30% less likely to develop breast cancer.
A large study found women taking Ozempic, Wegovy, Mounjaro, or Zepbound were about 30% less likely to develop breast cancer.
The record remains open to additional disclosures.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/top/health/